FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to uPARAP conjugates, in particular antibody-drug conjugates (ADC) containing monoclonal antibodies, directed against the N-terminal region of uPARAP, and use thereof in delivering active agents to uPARAP expressing cells and tissues. Present invention also relates to use of said ADC in treating diseases characterized by the presence of uPARAP expressing cells, such as a malignant tumor.
EFFECT: invention provides higher clinical effectiveness in diseases characterized by the presence of uPARAP expressing cells, such as malignant tumor.
47 cl, 18 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
